Antitumor

A novel combination of triple immunotherapy improves antitumor responses in preclinical models of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a poor prognosis and limited treatment options. Researchers at Rutgers Cancer Institute of New Jersey, the state’s leading cancer program and the only National Cancer Institute-designated Comprehensive Cancer Center, along with RWJBarnabas Health, in collaboration with researchers at MD Anderson Cancer Center, have discovered a …

A novel combination of triple immunotherapy improves antitumor responses in preclinical models of pancreatic cancer Read More »

JITC Publication on the Mechanism of Akes’ Ligufalimab (a CD47 Monoclonal Antibody) Shows Promising Antitumor Efficacy and a Favorable Safety Profile

HONG KONG, December 11, 2022 /PRNewswire/ — Akeso Inc. (9926. HK) (“Akeso”) announced today that the Journal for Immunotherapy of Cancer (JITC), a BMJ oncology journal, has published the mechanism of action of its Ligufalimab (AK117). The title of the article is “Ligufalimab, a novel non-hemagglutination-free anti-CD47 antibody that shows both monotherapy and combination antitumor …

JITC Publication on the Mechanism of Akes’ Ligufalimab (a CD47 Monoclonal Antibody) Shows Promising Antitumor Efficacy and a Favorable Safety Profile Read More »